Filing Details

Accession Number:
0001415889-24-022427
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-28 16:15:14
Reporting Period:
2024-08-26
Accepted Time:
2024-08-28 16:15:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1660334 Verrica Pharmaceuticals Inc. VRCA Pharmaceutical Preparations (2834) 463137900
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1805359 G. Christopher Hayes C/O Verrica Pharmaceuticals Inc.
44 West Gay Street, Suite 400
West Chester PA 19380
Chief Legal Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-08-26 26,183 $2.66 115,303 No 4 S Direct
Common Stock Disposition 2024-08-27 9,530 $2.46 105,773 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
  3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.53 inclusive.